Epilepsy in brain tumor patients

Current Opinion in Neurology

Volumn 23, Issue 6, 2010, Pages 603-609

  Rossetti, Andrea O ^a   Stupp, Roger ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

anti epileptic drug; astrocytoma; glioma; levetiracetam; pregabalin

Indexed keywords

CARBAMAZEPINE; CARMUSTINE; CEDIRANIB; CYTOCHROME P450; ERLOTINIB; ETIRACETAM; ETOPOSIDE; FOTEMUSTINE; GABAPENTIN; HARKOSERIDE; IMATINIB; IRINOTECAN; LAMOTRIGINE; LIVER ENZYME; LOMUSTINE; NIMUSTINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TEMOZOLOMIDE; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ADD ON THERAPY; ANTICONVULSANT THERAPY; ANXIETY DISORDER; ASTROCYTOMA; ATAXIA; BRAIN METASTASIS; BRAIN TUMOR; CLINICAL TRIAL; DIPLOPIA; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPILEPSY; EPILEPTOGENESIS; ERECTILE DYSFUNCTION; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; LONG TERM CARE; LYMPHOMA; MENINGIOMA; NEUTROPENIA; PLASMA HALF LIFE; RECURRENCE RISK; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; SOMNOLENCE; THROMBOCYTOPENIA; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTICONVULSANTS; BRAIN NEOPLASMS; CLINICAL PROTOCOLS; EPILEPSY; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78649594194     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833e996c     Document Type: Review

References (52)

1. Olafsson E, Ludvigsson P, Gudmundsson G, et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 2005; 4:627-634.
2. Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis 2004; 1 (Suppl 1):S27-S33.
3. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453-468.
4. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6:421-430.
5. Wolf HK, Roos D, Blumcke I, et al. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol 1996; 91:376-384.
6. Rosati A, Tomassini A, Pollo B, et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol 2009; 93:395-400.
7. Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010; 67:336-342.
8. Rosati A, Marconi S, Pollo B, et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol 2009; 93:319-324.
9. Brodtkorb E, Nakken KO, Steinlein OK. No evidence for a seriously increased malignancy risk in LGI1-caused epilepsy. Epilepsy Res 2003; 56:205-208.
10. Piepoli T, Jakupoglu C, Gu W, et al. Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neuro Oncol 2006; 8:96-108.
11. Berntsson SG, Malmer B, Bondy ML, et al. Tumor-associated epilepsy and glioma: are there common genetic pathways? Acta Oncol 2009; 48:955-963.
12. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:1886-1893.
13. Chang BS, Lowenstein DH. Practice parameter: antiepilepticdrug prophylaxis in severe traumatic brain injury. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 60:10-16.
14. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010; 12:165-172.
15. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71:665-669.
16. Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2007; 107:253-260. (Pubitemid 47219366)
17. Shah D, Husain AM. Utility of levetiracetam in patients with subarachnoid hemorrhage. Seizure 2009; 18:676-679.
18. Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005; 65:212-215.
19. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46:470-472. (Pubitemid 40470667)
20. Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009; 73:1207-1213.
21. Rosenow F, Reif PS, Haag A, et al. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2010; 74:1330-1331; author reply 1331.
22. Rossetti AO, Stupp R. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2010; 74:1329; author reply 1329-1330.
23. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003; 9:2940-2949.
24. Armijo JA, Sanchez MB, Campos C, Adin J. The interactions of antiepileptic drugs in oncology practice. Rev Neurol 2006; 42:681-690.
25. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000; 356:285-290.
26. Ruegg S. Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med Wkly 2002; 132:425-426.
27. Eyal S, Yagen B, Sobol E, et al. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45:737-744.
28. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006; 6:2.
29. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005; 72:255-260.
30. Bourg V, Lebrun C, Chichmanian RM, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12:217-219.
31. Anderson GD, Lin YX, Berge C, Ojemann GA. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997; 87:252-256.
32. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second-and third-generation antiepileptic drugs. Expert Rev Neurother 2010; 10:119-140.
33. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101:9861-9866.
34. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47:77-90.
35. Helmstaedter C, Fritz NE, Kockelmann E, et al. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 2008; 13:535-541.
36. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356:1255-1259.
37. Wagner GL, Wilms EB, Van Donselaar CA, Vecht Ch J. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003; 12:585-586.
38. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 2009; 93:349-354.
39. Rosati A, Buttolo L, Stefini R, et al. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 2010; 67:343-346.
40. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamo-trigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46:1407-1413.
41. Ramsay RE, Perucca E, Robbins J, et al. Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. Epilepsia 2009; 50:1891-1898.
42. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 1996; 23:128-131.
43. Khan RB, Hunt DL, Thompson SJ. Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 2004; 19:97-101.
44. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 2009; 111:171-173.
45. Maschio M, Albani F, Jandolo B, et al. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neurooncol 2008; 90:217-221.
46. Pursche S, Schleyer E, von Bonin M, et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008; 3:198-203.
47. Maschio M, Dinapoli L, Zarabla A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 2008; 86:61-70.
48. Lu Y, Yu W, Wang X. Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation. CNS Drugs 2009; 23:351-359.
49. Maschio M, Dinapoli L, Saveriano F, et al. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 2009; 120:210-212.
50. Maschio M, Dinapoli L, Vidiri A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 2009; 28:60.
51. Maschio M, Dinapoli L, Gomellini S, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol 2010; 98:109-116.
52. Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia 2006; 47:1237-1238.